Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Methylprednisolone and prednisone taper for vaso-occlusive crises in sickle cell disease
NCT00263562Phase 3Terminated
- Sponsor
- Baylor College of Medicine
- Start
- Dec 2005
- Primary completion
- Jun 2008
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of methylprednisolone and prednisone in sickle cell disease (SCD) and vaso-occlusive crisis (VOC), sponsored by Baylor College of Medicine. Primary endpoint: Pain Scores at 30 days. Started Dec 2005; status: terminated.
02
Drugs
methylprednisoloneprednisone
03
Conditions
sickle cell disease (SCD)vaso-occlusive crisis (VOC)
Beyond the preview
Go deeper on NCT00263562.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00263562.